Long-Chain Fatty Acid Oxidation Disorders In-Clinic Disease Monitoring Program
← catalyst calendarNCT04632953 · readout ≤ 3,420 d
Sponsored by Ultragenyx Pharmaceutical Inc (industry) · RARE — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
150actual
Sites
16
Countries
Canada, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-11-30 | actual | When the study began enrolling |
| Primary completion | Dec 2035 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2035 | estimated | The whole study's end, after follow-up |
| First posted | 2020-11-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)
Intervention
- Other: No Intervention
Primary outcomes
what the primary-completion date above is the date OFLong-Term Safety of Patients With LC-FAOD as Assessed by Incidence, Severity, and Frequency of Serious Adverse Events (SAEs) and Adverse Events (AEs) in Pregnant and Lactating Patients with LC-FAOD
measured 10 Years
Long-Term Safety of Patients With LC-FAOD as Assessed by Outcomes of Pregnancy in Patients with LC-FAOD
measured 10 Years
Long-Term Safety of Patients With LC-FAOD as Assessed by Incidence, Frequency, and Severity of SAEs and AEs During the First Year of Life in Infants Born to Study Participants
measured 10 Years
Long-Term Safety of Patients With LC-FAOD as Assessed by Incidence of SAEs Assessed as Related to Triheptanoin Treatment by Study Investigator
measured 10 Years
Long-Term Safety of Patients With LC-FAOD as Assessed by Incidence of All Colon Cancer or Gastrointestinal (GI) Cancer, GI Dysplasia, and GI Neoplasia, SAEs and AEs Reported for All Patients With LC-FAOD
measured 10 Years
Permalink · RARE's whole pipeline · Catalyst calendar · Every registered study · What changed